Roche (OTCQX:RHHBY) (OTCQX:RHHBF) will finalize the acquisition of Poseida Therapeutics (NASDAQ:PSTX), a biopharmaceutical ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Blue Giant Acquisition Corp. has ...

Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics , a ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

Poseida Therapeutics Inc (PSTX) stock saw a modest uptick, ending the day at $9.56 which represents a slight increase of $0.04 or 0.42% from the prior close of $9.52. The stock opened at $9.52 and ...

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Free Report) hit a new 52-week high on Tuesday . The stock traded as ...

Poseida Therapeutics Inc (PSTX) stock saw a decline, ending the day at $9.4 which represents a decrease of $-0.20 or -2.08% from the prior close of $9.6. The stock opened at $9.54 and touched a low of ...

Recent health news includes Donald Trump's consideration of an executive order on gas stoves, Roche's acquisition of Poseida, ...

California biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last week, seeking $115 million in funding for projects including a CAR-T ...

German retail sales unexpectedly fell by 0.6% in November compared with the previous month, official data showed on Wednesday ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and not ...